(RTTNews) - Friday, Profound Medical Corp. (PROF) and Telix Pharmaceuticals Limited (TLX) announced a co-education agreement to educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided T
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.